Cargando…

Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension

Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH). We hypothesized that heart‐relevant microRNAs, that is myomiRs (miR‐1, miR‐133a, miR‐208, miR‐499) and miR‐214, can have a role in the right ventricle in the development of PAH. To mimic PAH, male...

Descripción completa

Detalles Bibliográficos
Autores principales: Kmecova, Zuzana, Veteskova, Jana, Lelkova‐Zirova, Katarina, Bies Pivackova, Lenka, Doka, Gabriel, Malikova, Eva, Paulis, Ludovit, Krenek, Peter, Klimas, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299706/
https://www.ncbi.nlm.nih.gov/pubmed/32395887
http://dx.doi.org/10.1111/jcmm.15352
_version_ 1783547444210958336
author Kmecova, Zuzana
Veteskova, Jana
Lelkova‐Zirova, Katarina
Bies Pivackova, Lenka
Doka, Gabriel
Malikova, Eva
Paulis, Ludovit
Krenek, Peter
Klimas, Jan
author_facet Kmecova, Zuzana
Veteskova, Jana
Lelkova‐Zirova, Katarina
Bies Pivackova, Lenka
Doka, Gabriel
Malikova, Eva
Paulis, Ludovit
Krenek, Peter
Klimas, Jan
author_sort Kmecova, Zuzana
collection PubMed
description Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH). We hypothesized that heart‐relevant microRNAs, that is myomiRs (miR‐1, miR‐133a, miR‐208, miR‐499) and miR‐214, can have a role in the right ventricle in the development of PAH. To mimic PAH, male Wistar rats were injected with monocrotaline (MCT, 60 mg/kg, s.c.); control group received vehicle. MCT rats were divided into two groups, based on the clinical presentation: MCT group terminated 4 weeks after MCT administration and prematurely terminated group (ptMCT) displaying signs of terminal disease. Myocardial damage genes and candidate microRNAs expressions were determined by RT‐qPCR. Reduced blood oxygen saturation, breathing disturbances, RV enlargement as well as elevated levels of markers of myocardial damage confirmed PH in MCT animals and were more pronounced in ptMCT. MyomiRs (miR‐1/miR‐133a/miR‐208a/miR‐499) were decreased and the expression of miR‐214 was increased only in ptMCT group (P < 0.05). The myomiRs negatively correlated with Fulton index as a measure of RV hypertrophy in MCT group (P < 0.05), whereas miR‐214 showed a positive correlation (P < 0.05). We conclude that the expression of determined microRNAs mirrored the disease severity and targeting their pathways might represent potential future therapeutic approach in PAH.
format Online
Article
Text
id pubmed-7299706
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72997062020-06-18 Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension Kmecova, Zuzana Veteskova, Jana Lelkova‐Zirova, Katarina Bies Pivackova, Lenka Doka, Gabriel Malikova, Eva Paulis, Ludovit Krenek, Peter Klimas, Jan J Cell Mol Med Original Articles Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH). We hypothesized that heart‐relevant microRNAs, that is myomiRs (miR‐1, miR‐133a, miR‐208, miR‐499) and miR‐214, can have a role in the right ventricle in the development of PAH. To mimic PAH, male Wistar rats were injected with monocrotaline (MCT, 60 mg/kg, s.c.); control group received vehicle. MCT rats were divided into two groups, based on the clinical presentation: MCT group terminated 4 weeks after MCT administration and prematurely terminated group (ptMCT) displaying signs of terminal disease. Myocardial damage genes and candidate microRNAs expressions were determined by RT‐qPCR. Reduced blood oxygen saturation, breathing disturbances, RV enlargement as well as elevated levels of markers of myocardial damage confirmed PH in MCT animals and were more pronounced in ptMCT. MyomiRs (miR‐1/miR‐133a/miR‐208a/miR‐499) were decreased and the expression of miR‐214 was increased only in ptMCT group (P < 0.05). The myomiRs negatively correlated with Fulton index as a measure of RV hypertrophy in MCT group (P < 0.05), whereas miR‐214 showed a positive correlation (P < 0.05). We conclude that the expression of determined microRNAs mirrored the disease severity and targeting their pathways might represent potential future therapeutic approach in PAH. John Wiley and Sons Inc. 2020-05-12 2020-06 /pmc/articles/PMC7299706/ /pubmed/32395887 http://dx.doi.org/10.1111/jcmm.15352 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Kmecova, Zuzana
Veteskova, Jana
Lelkova‐Zirova, Katarina
Bies Pivackova, Lenka
Doka, Gabriel
Malikova, Eva
Paulis, Ludovit
Krenek, Peter
Klimas, Jan
Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension
title Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension
title_full Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension
title_fullStr Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension
title_full_unstemmed Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension
title_short Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension
title_sort disease severity–related alterations of cardiac micrornas in experimental pulmonary hypertension
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299706/
https://www.ncbi.nlm.nih.gov/pubmed/32395887
http://dx.doi.org/10.1111/jcmm.15352
work_keys_str_mv AT kmecovazuzana diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT veteskovajana diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT lelkovazirovakatarina diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT biespivackovalenka diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT dokagabriel diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT malikovaeva diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT paulisludovit diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT krenekpeter diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension
AT klimasjan diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension